Special Issue "Discovery and Development of New Antimycobacterial Agents"
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 831
Interests: drug discovery; tuberculosis; molecular dynamics; therapeutic drugs toxicology
We would like to invite you to submit your research papers on drug development for tuberculosis (TB) treatment to the Pharmaceuticals Special Issue "Discovery and Development of New Antimycobacterial Agents". TB continues to be a major global health challenge, and it is essential to put together the latest advancements in drug development to address this critical issue. Your contribution to this field is valuable, and we believe that a manuscript of your work can impact the fight against TB.
The papers should cover the current state-of-the-art in drug development for tuberculosis, including innovative approaches to the discovery, development, and delivery of new treatments. The scope of the papers can also include in silico, in vitro, preclinical and clinical studies, pharmacokinetics, pharmacodynamics, and toxicity.
Potential topics to be covered include, but are not limited to:
- Chemical development of novel and effective antimycobacterial drugs;
- In silico drug design with at least in vitro results corroborating the computational analysis;
- Evaluation of natural product derivatives’ efficacy against Mycobacterium;
- Novel drug repurposing proposals with at least in vitro results;
- New strategies to avoid or overcome drug resistance;
- Evaluation of new molecular targets, evidencing their potential effectiveness in therapeutics;
- Innovative drug delivery systems for TB treatment;
- Cutting-edge approaches to the development of original and functional antimycobacterial drugs.
Dr. Maurício Homem-De-Mello
Prof. Dr. Pérola de Oliveira Magalhães
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- drug discovery
- drug design
- drug repurposing
- TB molecular targets
- TB drug delivery systems